Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Mar 08, 2021 3:21pm
121 Views
Post# 32745092

RE:RE:RE:Warrant question

RE:RE:RE:Warrant questionI should probably just add that the WS warrants are a little strange.

When I search price on RBC I have to enter the ticker szls.wt.s for a quote but when I purchase I purchase using the ticker szls.ws. 

These links also show the number of warrants outstanding for both wt and ws.  Note the ws is shown as wis:

https://www.marketwatch.com/investing/stock/szls.wis?countrycode=ca
https://www.marketwatch.com/investing/stock/szls.wt?countrycode=ca

And the wt warrants are listed on canadian warrants the ws wwarrants are not.  Canadian warrants has a very good FAQ section too

https://canadianwarrants.com/info/faq.htm
https://canadianwarrants.com/values/current.htm#axzz6oYOYShab





 
LithLover wrote: Warrants szls.wt or szls.ws  

The WT warrants require 8 warrants for 1 share so at a current price of $0.08 you need 8 or $0.64 total add an exercise price of $.0.72 total is $1.36 for 1 share.  Expire date is June 2023,   There are just under 80 million warrants so 10 million shares could be purchased if all are exercised. 

The WS warrants require 1 warrant for 1 share.  Current price is $0.475 and add an exercise price of $1.10 total is $1.575 for 1 share.  They expire Dec 2023 so additional 6 months past the WT warrants.  Just under 5 million outstanding so less liquid and tougher to trade.  5 million shares could be purchased if all are exercised.  




davewho wrote: WTs were pre RS of 8 to 1 so you need 8 plus the strike price to buy 1 share. Which is why they are cheaper than the WS series




<< Previous
Bullboard Posts
Next >>